Nu Skin Enterprises, Inc. NUS R2K
Company Overview
Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa, ageLOC LumiSpa iO, and Nu Skin RenuSpa iO; ageLOC TruFace and ageLOC LumiSpa cleansers and devices; Prysm iO, a data-enabled wellness device; and Nutricentials beauty and Beauty Focus wellness brands. The company also provides wellness products, such as ageLOC TRME, LifePak, and Beauty Focus. In addition, it is the research and product development of skin care products, nutritional supplements, and devices. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center and independent marketers. It serves Mainland China; South Korea; Southeast Asia/Pacific, which includes Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Australia, New Zealand and other markets; Americas, comprising Canada, Latin America and the United States; Japan; Hong Kong/Taiwan, consists of Macau; and Europe & Africa, which includes markets in Europe as well as South Africa. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
Why Investors Should Care
Trades at a P/E of 4.6, below the sector median of 20.9.
Carries low leverage with a debt-to-equity ratio of 0.38.
Offers a dividend yield of 4.39%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.49B (-14.3% YoY); net profit $160.20M.
- Trailing 12 Months Year-on-year growth — revenue -12.0%, earnings -98.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.7%, profit CAGR 5.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.69% |
| 1 Year: | -12.00% |
Compounded Profit Growth
| 5 Years: | 5.42% |
| 1 Year: | -98.20% |
Stock Price Performance
| 1 Year: | -40.92% |
| 6 Months: | -51.06% |
| 3 Months: | -33.15% |
| 1 Month: | -8.64% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.45 · Neutral
P/E of 4.60 is below the sector median of 20.95 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 4.39%.
- Generates positive free cash flow.
CONS
- Trading 60.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NUS Nu Skin Enterprises, Inc. R2K | 4.97 | 4.60 | $241.30M | 4.39% | 5.76% | 7.04% | 0.69% | 5.42% |
| 2 | WMT Walmart Inc. SPX | 113.70 | 40.04 | $904.83B | 0.89% | 18.21% | 24.13% | 5.27% | 23.30% |
| 3 | COST Costco Wholesale Corporation NDXSPX | 921.75 | 46.46 | $408.78B | 0.60% | 25.96% | 29.15% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPX | 83.08 | 26.13 | $357.45B | 2.57% | 16.47% | 43.37% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPX | 146.08 | 21.36 | $340.16B | 2.85% | 22.93% | 31.11% | 0.36% | 1.66% |
| 6 | PM Philip Morris International Inc. SPX | 175.95 | 24.78 | $274.23B | 3.19% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPX | 135.45 | 21.23 | $185.13B | 4.10% | 15.41% | 43.88% | 4.93% | 2.11% |
| 8 | MO Altria Group, Inc. SPX | 70.16 | 14.65 | $117.16B | 5.89% | 38.27% | - | 1.24% | -1.89% |
| 9 | MNST Monster Beverage Corporation NDXSPX | 98.00 | 47.34 | $95.84B | 0.00% | 28.33% | 26.65% | 13.03% | 14.82% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 499.10M | 550.10M | 563.70M | 616.22M | 704.19M | 675.31M | 623.62M | 623.50M | 589.93M | 518.03M | 612.37M | 703.35M | 677.03M | 704.05M | 641.15M | 604.90M | 560.62M | 537.80M | 481.46M | 500.26M | 498.77M | 417.31M | 439.08M | 430.14M | 364.49M | 386.14M | 364.21M | 320.61M |
| Gross Profit | 891.10M | 564.40M | 494.00M | 529.50M | 503.10M | 438.28M | 449.95M | 418.55M | 450.80M | 333.96M | 472.27M | 478.30M | 387.83M | 428.58M | 442.87M | 469.94M | 535.64M | 517.86M | 476.96M | 469.47M | 449.77M | 392.24M | 458.26M | 519.97M | 506.46M | 532.08M | 482.25M | 443.40M | 412.51M | 364.31M | 347.87M | 364.71M | 292.27M | 294.06M | 307.18M | 301.46M | 246.96M | 265.73M | 256.72M | 214.46M |
| Operating Income | 188.60M | 101.20M | 54.70M | 105.00M | 91.30M | 68.65M | 71.80M | 42.54M | 61.70M | 8.15M | 79.80M | 82.37M | 46.26M | 64.74M | 64.36M | 58.99M | 82.76M | 80.67M | 68.65M | 74.20M | 69.89M | 36.56M | 58.07M | 74.23M | 62.91M | 85.38M | 65.38M | 52.15M | 51.53M | -20.28M | 16.06M | 42.51M | -26.36M | 8.82M | -125.56M | 18.23M | -9.90M | 30.78M | 21.64M | 4.03M |
| Net Income | 125.30M | 54.90M | 19.50M | 68.30M | 46.50M | 36.28M | 44.66M | 16.27M | 35.80M | 3.32M | 44.71M | 56.87M | 27.49M | 42.04M | 41.67M | 35.54M | 50.96M | 53.15M | 43.00M | 46.35M | 44.09M | 19.73M | 41.85M | 56.31M | 47.43M | 59.34M | 49.73M | 38.72M | 34.24M | -25.39M | 11.38M | 26.89M | -36.95M | -533.00K | -118.26M | 8.30M | 107.52M | 21.12M | 17.08M | 1.84M |
| Diluted EPS | 2.02 | 0.90 | 0.32 | 1.12 | 0.77 | 0.60 | 0.75 | 0.28 | 0.62 | 0.06 | 0.79 | 0.98 | 0.51 | 0.77 | 0.76 | 0.64 | 0.90 | 0.94 | 0.77 | 0.83 | 0.79 | 0.36 | 0.81 | 1.08 | 0.91 | 1.15 | 0.97 | 0.76 | 0.67 | -0.51 | 0.23 | 0.54 | -0.74 | -0.01 | -2.38 | 0.17 | 2.14 | 0.43 | 0.34 | 0.04 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 1.33B | 1.54B | 1.72B | 2.13B | 3.18B | 2.57B | 2.25B | 2.21B | 2.28B | 2.68B | 2.42B | 2.58B | 2.70B | 2.23B | 1.97B | 1.73B | 1.49B |
| Gross Profit | 1.02B | 1.09B | 1.26B | 1.40B | 1.78B | 2.67B | 2.09B | 1.76B | 1.71B | 1.78B | 2.04B | 1.84B | 1.92B | 2.02B | 1.59B | 1.36B | 1.18B | 1.03B |
| Operating Income | 125.43M | 147.71M | 217.06M | 233.74M | 340.84M | 554.11M | 352.19M | 244.70M | 231.10M | 274.48M | 240.86M | 267.43M | 257.56M | 233.99M | 110.85M | 48.27M | -151.59M | 65.76M |
| Net Income | 65.35M | 89.84M | 136.05M | 153.33M | 221.65M | 364.89M | 189.18M | 133.05M | 143.09M | 129.44M | 121.89M | 173.55M | 191.35M | 147.27M | 104.78M | 8.60M | -146.59M | 160.20M |
| Diluted EPS | 1.02 | 1.40 | 2.11 | 2.38 | 3.52 | 5.94 | 3.11 | 2.25 | 2.55 | 2.36 | 2.16 | 3.10 | 3.63 | 2.86 | 2.07 | 0.17 | -2.95 | 3.18 |
| R&D Expense | - | 10.40M | 12.40M | 13.60M | 14.90M | 18.00M | 18.90M | 20.10M | 24.30M | 22.00M | 23.00M | 30.10M | 23.30M | 27.20M | 23.30M | 22.60M | 13.00M | 10.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 748.45M | 892.22M | 990.96M | 1.12B | 1.82B | 1.61B | 1.51B | 1.47B | 1.59B | 1.69B | 1.77B | 1.96B | 1.91B | 1.82B | 1.81B | 1.47B | 1.41B |
| Total Equity | 275.01M | 316.18M | 375.69M | 471.25M | 574.24M | 590.61M | 858.62M | 942.44M | 825.62M | 664.07M | 704.60M | 781.87M | 875.29M | 894.27M | 912.77M | 897.30M | 821.97M | 651.46M | 805.24M |
| Cash & Equivalents | 87.33M | 114.59M | 158.04M | 230.34M | 272.97M | 320.02M | 525.15M | 288.42M | 289.35M | 357.25M | 426.40M | 386.91M | 335.63M | 402.68M | 339.59M | 264.73M | 256.06M | 186.88M | 238.63M |
| Long Term Debt | - | - | 121.12M | 133.01M | 107.94M | 154.96M | 113.85M | 164.57M | 181.75M | 334.17M | 310.79M | 361.01M | 334.46M | 305.39M | 268.78M | 377.47M | 478.04M | 363.61M | 204.19M |
| Total Liabilities | - | - | 372.76M | 420.98M | 416.72M | 534.20M | 962.44M | 672.00M | 680.22M | 809.98M | 885.28M | 912.58M | 893.72M | 1.06B | 993.71M | 923.67M | 986.66M | 817.46M | 600.07M |
| Current Liabilities | - | - | 185.21M | 216.45M | 241.17M | 320.10M | 776.79M | 418.33M | 407.60M | 399.01M | 447.37M | 439.65M | 356.76M | 542.86M | 529.69M | 359.24M | 328.87M | 296.61M | 263.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 103.31M | 133.94M | 187.88M | 224.31M | 310.98M | 530.18M | - | 322.11M | 275.26M | 302.56M | 202.74M | 177.93M | 379.14M | 141.58M | 108.06M | 118.64M | 111.74M | 80.29M |
| Investing Cash Flow | -10.78M | -20.21M | -53.78M | -71.20M | -104.86M | -193.70M | - | -60.85M | -57.86M | -91.96M | -108.76M | -71.41M | -79.43M | -88.73M | -67.08M | -134.50M | -37.96M | 170.66M |
| Financing Cash Flow | -62.69M | -73.01M | -69.02M | -107.01M | -163.89M | -120.72M | - | -235.92M | -134.71M | -159.57M | -116.71M | -154.79M | -245.17M | -104.70M | -99.50M | 10.73M | -133.18M | -202.40M |
| Capital Expenditure | -16.01M | -20.21M | -53.78M | -41.81M | -96.64M | -185.10M | -101.48M | -56.62M | -50.22M | -60.16M | -70.37M | -66.07M | -63.82M | -68.61M | -59.06M | -58.49M | -41.58M | -34.28M |
| Free Cash Flow | 87.30M | 113.73M | 134.10M | 182.51M | 214.33M | 345.07M | - | 265.49M | 225.04M | 242.40M | 132.37M | 111.86M | 315.32M | 72.97M | 49.01M | 60.15M | 70.16M | 46.01M |
| Share Buybacks | 6.09M | 21.14M | 58.52M | 67.15M | 201.47M | 140.87M | 45.72M | 164.09M | 247.21M | 71.73M | 69.56M | 825.00K | 144.33M | 80.42M | 70.05M | 13.01M | 0 | 20.04M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 81.7% | 82.3% | 81.2% | 83.4% | 84.1% | 81.4% | 78.2% | 77.3% | 78.0% | 76.3% | 76.0% | 74.5% | 75.0% | 71.7% | 68.9% | 68.2% | 69.4% |
| Operating Margin % | - | 11.1% | 14.1% | 13.6% | 16.0% | 17.4% | 13.7% | 10.9% | 10.5% | 12.0% | 9.0% | 11.0% | 10.0% | 8.7% | 5.0% | 2.5% | -8.8% | 4.4% |
| Net Margin % | - | 6.7% | 8.9% | 8.9% | 10.4% | 11.5% | 7.4% | 5.9% | 6.5% | 5.7% | 4.5% | 7.2% | 7.4% | 5.5% | 4.7% | 0.4% | -8.5% | 10.8% |
| ROE % | 20.7% | 23.9% | 28.9% | 26.7% | 37.5% | 42.5% | 20.1% | 16.1% | 21.5% | 18.4% | 15.6% | 19.8% | 21.4% | 16.1% | 11.7% | 1.0% | -22.5% | 19.9% |
| ROCE % | - | 26.2% | 32.1% | 31.2% | 42.4% | 53.1% | 29.4% | 22.3% | 21.5% | 24.0% | 19.2% | 18.9% | 18.2% | 17.0% | 7.6% | 3.3% | -12.9% | 5.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.84% | 4.29M | $21.59M |
| 2 | Charles Schwab Investment Management, Inc. | 4.41% | 2.14M | $10.78M |
| 3 | Vanguard Capital Management LLC | 4.25% | 2.06M | $10.38M |
| 4 | American Century Companies Inc | 4.16% | 2.02M | $10.17M |
| 5 | Prescott Group Capital Management, L.L.C. | 3.70% | 1.79M | $9.03M |
| 6 | Acadian Asset Management. LLC | 3.63% | 1.76M | $8.87M |
| 7 | Dimensional Fund Advisors LP | 3.57% | 1.74M | $8.73M |
| 8 | Vanguard Portfolio Management LLC | 3.52% | 1.71M | $8.60M |
| 9 | Renaissance Technologies, LLC | 3.50% | 1.70M | $8.55M |
| 10 | AQR Capital Management, LLC | 2.55% | 1.24M | $6.22M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NUS
Nu Skin (NUS) Soars 6.9%: Is Further Upside Left in the Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPZFVjaXRmTGljVmxRWDRnSU1VYW5oT3VDT1JDb1NxaUZhejZUekJuQW0tbEVabERxSml4dzJXZ0VfX3oySzRPVHlOSHBYekVMeVBiQmRiYUlSSUJpa19uS3Y0NV9NaGxlM0xZMktNWGcyY3VKeEctUkVfY0JhcXNLbjFjNDhvWG9EV1BJMQ…
(NUS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxONDNId1VwVkZhZ0liTjFqcUt5TXZfUkdlaUNsSkVfcHYzQms1ZnduelF1UWN1TVhHLVZCSDZWY2NKdHI2LU9uSHZ3RzZERHhVOFU2Mm5sNWRTTlRCdzVRTkJERkt3VTVmeTdEQmdJWDJ4V05wUWttSTdYRWx0ZEtPNGIzRk42Vkh4MGFhQV…
Nu Skin Enterprises, Inc.'s (NYSE:NUS) Share Price Could Signal Some Risk - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPNVpNcWUxWVE4b3U2V0x4Q3dlS0g3cDFHLVVVVXJfaFU2bU9WcDVaWlpPVU9WRFNFUEZaX0FnaHI2cWJLZ1RQMDYwNGtXX0hsc3BKS3Y3WlY0TlJjX05fa0pqY09abFU2QTloWVg3V3YzbjVvQTRvek53bUZDaGRLWUV6OWNpQVY4d25zek…
Nu Skin (NUS) director sells 7,203 shares and gets 26,643-share grant - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPVDNoa2xkZTktWEo0TU4xMVBQeXVFQ1ZJSTljejNGZVN6LWhJaEUwS1lnNlFHNTh0blNKaHhPUjk2ckQ2clNBdHgzN0RyN0JOdldxdXZVdWFua2NHNEFrdGpCUnNtLTE4aWs0RUFZR01qLUw0TzVSVEh1YTR2dXZBRnpINWFvM0lTRTRGZG…
Nu Skin Enterprises (NUS) Q4 Earnings and Revenues Miss Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTFBZWnV3WG93WUVsRnZhYi15RDB5ZWNMQzFCc1hwa1luRjVDX0dhWnlody16QVU3XzRRSjlLUVN0WkdoNlNhbGNuWWk3X3F1dTQ5ZTRKVG41dmZzN0ZZS0NJbUJBZkdhNFYwR0RQbTRYRGZYOEsyVHFiNUIwWFU?oc=5" target="_blank">…
Insider Sell: James Winett Sells Shares of Nu Skin Enterprises I - GuruFocus
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPS3hLVkh5UHByRXJCdnI0OWhTVUZKX2NOdEhHWklEWUJ5ZzRzaExDZmVHS1JTeXNfQ0Nxd1d3b2c4SzNZclh1RjZrNFU4UGZ2d0J5R3VFcWJkemVGWVlZMC1TaUJ3UEstaVF4U1VZcnR2XzVFZ1VmSjBQWUpnUm9yU3ZRWW5JT0twellLT2…
NUS — Frequently Asked Questions
What is the current share price of Nu Skin Enterprises, Inc. (NUS)?
As of 2026-07-14 21:23 PDT, Nu Skin Enterprises, Inc. (NUS) trades at $4.97 on NYSE. Its 52-week range is $4.94 to $12.55.
What is the market capitalisation of NUS?
Nu Skin Enterprises, Inc. (NUS) has a market capitalisation of $241.30M on NYSE.
What is the P/E ratio of NUS?
NUS trades at a trailing price-to-earnings (P/E) ratio of 4.60. The industry average P/E is 20.95. Its price-to-book (P/B) ratio is 0.33.
Does NUS pay a dividend?
Nu Skin Enterprises, Inc. (NUS) currently offers a dividend yield of 4.39%.
What is the return on equity (ROE) of NUS?
NUS has a return on equity (ROE) of 7.04%. Its return on capital employed (ROCE) is 5.76%.
Is NUS a good stock to buy?
This page provides a data-driven analysis of Nu Skin Enterprises, Inc. (NUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.